These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 7335366)

  • 1. New regimen of combination hormone therapy (ME-TA-MAP) in the treatment of advanced breast cancer. A pilot study.
    Pannuti F; Martoni A; Fruet ; Marraro D; Strocchi E
    Panminerva Med; 1981; 23(3):157-60. PubMed ID: 7335366
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination therapy with progestins and tamoxifen in advanced breast cancer: A preliminary report.
    Trodella L; Ausilli-Cefaro GP; Turriziani A; Saccheri S; Venturo I; Minotti G
    Am J Clin Oncol; 1982 Oct; 5(5):495-9. PubMed ID: 6217741
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of combined tamoxifen and medroxyprogesterone treatment on coagulation-fibrinolytic systems in patients with advanced breast cancer.
    Fukutomi T; Adachi I; Watanabe T; Nanasawa T; Yamamoto H
    Acta Oncol; 1993; 32(5):573-4. PubMed ID: 8217244
    [No Abstract]   [Full Text] [Related]  

  • 4. [Endocrine treatment of metastasizing breast cancer in menopausal women. A randomized comparison between tamoxifen (Nolvadex) versus tamoxifen and medroxyprogesterone acetate (Clinovir)].
    Mouridsen HT; Ellemann K; Mattsson W; Palshof T; Daehnfeldt J; Rose C
    Ugeskr Laeger; 1979 Jul; 141(31):2113-6. PubMed ID: 483409
    [No Abstract]   [Full Text] [Related]  

  • 5. [Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer].
    Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
    Onkologie; 1982 Aug; 5 Suppl():34-41. PubMed ID: 6290955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethinyl estradiol and medroxyprogesterone treatment in advanced breast cancer: a pilot study.
    Pellegrini A; Massidda B; Mascia V; Ionta MT; Lippi MG; Muggiano A; Carboni E; Robustelli della Cuna G; Bernardo G; Strada MR; Pavesi L
    Cancer Treat Rep; 1981; 65(1-2):135-6. PubMed ID: 7226163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
    Dowsett M; Pfister C; Johnston SR; Miles DW; Houston SJ; Verbeek JA; Gundacker H; Sioufi A; Smith IE
    Clin Cancer Res; 1999 Sep; 5(9):2338-43. PubMed ID: 10499602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results.
    Pannuti F; Martoni A; Fruet F; Strocchi E; Di Marco AR
    Eur J Cancer (1965); 1980; Suppl 1():93-8. PubMed ID: 6459237
    [No Abstract]   [Full Text] [Related]  

  • 9. A pilot study of a high dose methotrexate regime in the management of advanced breast cancer.
    Penney GC; Roberts MM
    Clin Oncol; 1980 Dec; 6(4):385-6. PubMed ID: 7460412
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effects of combined hormone therapy on the coagulation-fibrinolytic systems in patients with advanced breast cancer].
    Fukutomi T; Adachi I; Watanabe T; Nanasawa T; Yamamoto H
    Gan To Kagaku Ryoho; 1993 May; 20(7):957-9. PubMed ID: 8489302
    [No Abstract]   [Full Text] [Related]  

  • 11. [Adjuvant endocrine therapy of breast cancer].
    Jonat W; Maass H
    ZFA (Stuttgart); 1983 Apr; 59(10):571-4. PubMed ID: 6868762
    [No Abstract]   [Full Text] [Related]  

  • 12. Weight loss during therapy for advanced breast cancer.
    Rowland-Payne CM; Abbott M; Jones JM; Powles TJ; Coombes RC
    Clin Oncol; 1982 Mar; 8(1):33-8. PubMed ID: 7075043
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II study of medroxyprogesterone acetate with tamoxifen in advanced renal cell cancer.
    Fuks JZ; Aisner J; Van Echo DA; Wiernik PH
    Cancer Treat Rep; 1982 Sep; 66(9):1773-4. PubMed ID: 7116354
    [No Abstract]   [Full Text] [Related]  

  • 14. Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863).
    Beex L; Rose C; Mouridsen H; Jassem J; Nooij M; Estape J; Paridaens R; Piccart M; Gorlia T; Lardenoije S; Baila L
    Eur J Cancer; 2006 Dec; 42(18):3178-85. PubMed ID: 17045796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A study on the efficacy of combination chemoendocrine therapy consisting of cyclophosphamide, adriamycin, UFT, and tamoxifen for advanced or recurrent breast cancer].
    Yamaguchi S; Fukuda M; Ota T; Nakayama Y; Ogata H; Shimizu K; Nishikawa T; Adachi Y; Fukuma E
    Gan To Kagaku Ryoho; 1999 Jul; 26(8):1145-52. PubMed ID: 10431580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Metastatic breast carcinoma: sequential hormonotherapy with tamoxifen and medroxy-progesterone acetate. preliminary results].
    Bosset JF; Pereal M; Hurteloup P; Altwegg T; Del Piano F; Colette C; Schraub S
    Bull Cancer; 1982; 69(2):170-1. PubMed ID: 7126890
    [No Abstract]   [Full Text] [Related]  

  • 17. [Chemotherapy in advanced breast cancer: experience in 100 cases (author's transl)].
    Modolell Roig A; Sans-Sabrafen J; Pardo Peret P; Rodríguez Ferrera JC; Boleda Relats M; Buxó Costa J; Galofré Folch M
    Med Clin (Barc); 1982 Mar; 78(6):211-7. PubMed ID: 7087579
    [No Abstract]   [Full Text] [Related]  

  • 18. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study.
    Jenkins V; Shilling V; Fallowfield L; Howell A; Hutton S
    Psychooncology; 2004 Jan; 13(1):61-6. PubMed ID: 14745746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Overall evaluation of the results of treatment of metastatic carcinomas of the breast with high doses of MAP combined with bromocryptin].
    Mussa A; Dogliotti L; Di Carlo F
    Minerva Med; 1980 Feb; 71(6):391-400. PubMed ID: 7360379
    [No Abstract]   [Full Text] [Related]  

  • 20. [Medroxyprogesterone acetate (MAP) in high doses in the treatment of breast cancer in advanced stages].
    Pannuti F; Di Marco AR; Martoni A; Fruet F; Strocchi E; Burroni P; Marraro D
    Minerva Ginecol; 1982 Nov; 34(11):977-9. PubMed ID: 7155427
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.